JPWO2022032004A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022032004A5 JPWO2022032004A5 JP2023507973A JP2023507973A JPWO2022032004A5 JP WO2022032004 A5 JPWO2022032004 A5 JP WO2022032004A5 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP WO2022032004 A5 JPWO2022032004 A5 JP WO2022032004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061895P | 2020-08-06 | 2020-08-06 | |
| US63/061,895 | 2020-08-06 | ||
| US202063074582P | 2020-09-04 | 2020-09-04 | |
| US63/074,582 | 2020-09-04 | ||
| US202163144657P | 2021-02-02 | 2021-02-02 | |
| US63/144,657 | 2021-02-02 | ||
| PCT/US2021/044801 WO2022032004A2 (en) | 2020-08-06 | 2021-08-05 | Anti-claudin 18.2 multi-specific antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537002A JP2023537002A (ja) | 2023-08-30 |
| JPWO2022032004A5 true JPWO2022032004A5 (enExample) | 2024-08-13 |
| JP7792395B2 JP7792395B2 (ja) | 2025-12-25 |
Family
ID=80117669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507973A Active JP7792395B2 (ja) | 2020-08-06 | 2021-08-05 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279152A1 (enExample) |
| EP (1) | EP4192879A4 (enExample) |
| JP (1) | JP7792395B2 (enExample) |
| KR (1) | KR20230070203A (enExample) |
| WO (2) | WO2022032003A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| US20250158109A1 (en) | 2022-05-31 | 2025-05-15 | Lg Energy Solution, Ltd. | Composite solid electrolyte for lithium secondary battery and preparation method thereof |
| CN118307678A (zh) * | 2023-06-07 | 2024-07-09 | 北京义翘神州科技股份有限公司 | 一种抗cldn18_2的抗体 |
| WO2024250437A1 (en) * | 2023-06-08 | 2024-12-12 | Antengene (Hangzhou) Biologics Co., Ltd. | Anti-cldn18.2 antibodies and diagnostic uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| CN106999566B (zh) * | 2014-10-03 | 2022-01-28 | 麻省理工学院 | 结合埃博拉病毒糖蛋白的抗体及其用途 |
| HK1250723A1 (zh) * | 2015-05-29 | 2019-01-11 | F. Hoffmann-La Roche Ag | 人源化抗埃博拉病毒糖蛋白抗体和使用方法 |
| CA2990398A1 (en) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
| AU2019270865B2 (en) * | 2018-05-18 | 2023-03-30 | LaNova Medicines Limited | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CN118955712A (zh) * | 2018-07-25 | 2024-11-15 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| MA53330A (fr) * | 2018-08-03 | 2021-06-09 | Amgen Inc | Constructions d'anticorps pour cldn18.2 et cd3 |
| US10522488B1 (en) * | 2018-10-31 | 2019-12-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Patterning polymer layer to reduce stress |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
-
2021
- 2021-08-05 EP EP21853256.2A patent/EP4192879A4/en active Pending
- 2021-08-05 US US18/019,728 patent/US20230279152A1/en active Pending
- 2021-08-05 JP JP2023507973A patent/JP7792395B2/ja active Active
- 2021-08-05 KR KR1020237007877A patent/KR20230070203A/ko active Pending
- 2021-08-05 WO PCT/US2021/044800 patent/WO2022032003A2/en not_active Ceased
- 2021-08-05 WO PCT/US2021/044801 patent/WO2022032004A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paul et al. | Cancer therapy with antibodies | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Scott et al. | Antibody therapy of cancer | |
| CN114634569B (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| Cao et al. | Bispecific antibodies as novel bioconjugates | |
| US20210024630A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US11787863B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| Zekri et al. | An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| JP2020523029A5 (enExample) | ||
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| Chen | Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| Holliger et al. | Engineering antibodies for the clinic | |
| Long et al. | Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma | |
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| JP2005510470A (ja) | 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物 | |
| JPWO2022032004A5 (enExample) | ||
| JPWO2021046331A5 (enExample) | ||
| JPWO2021216972A5 (enExample) |